Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1981435rdf:typepubmed:Citationlld:pubmed
pubmed-article:1981435lifeskim:mentionsumls-concept:C0014806lld:lifeskim
pubmed-article:1981435lifeskim:mentionsumls-concept:C0039651lld:lifeskim
pubmed-article:1981435lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1981435lifeskim:mentionsumls-concept:C0009528lld:lifeskim
pubmed-article:1981435lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:1981435pubmed:issue6lld:pubmed
pubmed-article:1981435pubmed:dateCreated1991-4-11lld:pubmed
pubmed-article:1981435pubmed:abstractTextThe effects of tetracycline, minocycline and erythromycin on complement activation in vitro were studied. At concentrations of 100 mg/l or less, these antibiotics did not inhibit the capacity of Propionibacterium acnes to cleave C3 in normal human serum or in serum chelated of Ca2+ allowing complement activation by the alternative pathway alone. The antibiotics had no effect (at 100 mg/l) on total haemolytic activity of complement in normal human serum. This study did not provide evidence to support the hypothesis that the efficacy of these antibiotics in the therapy of inflammatory acne vulgaris can be explained by inhibition of complement activation.lld:pubmed
pubmed-article:1981435pubmed:languageenglld:pubmed
pubmed-article:1981435pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1981435pubmed:citationSubsetIMlld:pubmed
pubmed-article:1981435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1981435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1981435pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1981435pubmed:statusMEDLINElld:pubmed
pubmed-article:1981435pubmed:issn0001-5555lld:pubmed
pubmed-article:1981435pubmed:authorpubmed-author:InghamEElld:pubmed
pubmed-article:1981435pubmed:issnTypePrintlld:pubmed
pubmed-article:1981435pubmed:volume70lld:pubmed
pubmed-article:1981435pubmed:ownerNLMlld:pubmed
pubmed-article:1981435pubmed:authorsCompleteYlld:pubmed
pubmed-article:1981435pubmed:pagination531-4lld:pubmed
pubmed-article:1981435pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:meshHeadingpubmed-meshheading:1981435-...lld:pubmed
pubmed-article:1981435pubmed:year1990lld:pubmed
pubmed-article:1981435pubmed:articleTitleThe effects of tetracyclines and erythromycin on complement activation in vitro.lld:pubmed
pubmed-article:1981435pubmed:affiliationDepartment of Immunology, University of Leeds, W. Yorkshire, England.lld:pubmed
pubmed-article:1981435pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1981435pubmed:publicationTypeIn Vitrolld:pubmed